Leslie M. Randall, MD, MAS

Leslie Randall, MD, MAS, offers closing thoughts on the future trajectory of ovarian cancer treatment.

An expert gynecologic oncologist comments on recent revisions to FDA-approved indications for PARP inhibitors in the treatment of ovarian cancer.

Leslie Randall, MD, MAS, reviews recent long-term data on PARP inhibitors in the treatment of ovarian cancer.

Clinical insights on how to manage adverse events for patients with ovarian cancer who are receiving PARP inhibitors.

An expert on ovarian cancer discusses factors that influence PARP inhibitor selection, when to initiate maintenance therapy, and how to counsel patients on PARP inhibitors.

Leslie Randall, MD, MAS, reviews the available treatment options for BRCA-mutated advanced ovarian cancer.

An overview of guideline recommendations for molecular testing in ovarian cancer.

Leslie Randall, MD, MAS, presents the case of a 55-year-old woman with BRCA-mutated ovarian cancer and provides her initial impressions.

Closing out her discussion on ovarian cancer, Leslie Randall, MD, shares closing advice for community physicians on optimal treatment strategies.

Leslie Randall, MD, considers the possibility of relapse in ovarian cancer and reviews treatment options available at recurrence.

Focused discussion on the safety profiles of PARP inhibitors in ovarian cancer and how these can be mitigated with proper dose management.

Shared insight on the selection of PARP inhibitors for maintenance therapy in ovarian cancer with deference to patient and disease factors.

A broad look at maintenance therapy selection and its use in ovarian cancer to improve patient outcomes.

Expert Leslie Randall, MD, discusses the case of a 71-year-old woman who is diagnosed with ovarian cancer. Dr. Randall reviews data with PARP inhibitors and rationale for use of maintenance therapy in patients with platinum-sensitive disease.

Leslie M. Randall, MD, associate professor of Gynecology/Oncology, University of California Irvine, discusses the use of olaparib as maintenance therapy in the treatment of patients with ovarian cancer.